nVision Medical is a clinical-stage medical device company based in Mountain View, CA, led by CEO and President Surbhi Sarna. The company has developed a micro-catheter product that enables in-office, incision-free access to the fallopian tubes without general anesthesia. It is focused on two use cases: cell collection from the fallopian tube and direct visualization of the fallopian tube lumen. Earlier in the year nVision obtained the first FDA clearance for a device that collects cells from the fallopian tube and performed a First-in-Human case for its visualization device. The company holds patented micro-catheter technology and will use new funds to advance product development, conduct clinical studies, and pursue regulatory submissions. The articles report the company is in the clinical stage and actively progressing toward broader clinical validation and regulatory milestones. nVision Medical is developing two in-office diagnostic devices for women’s health: a catheter-based, pap-smear-like test intended for early ovarian cancer detection and a hydraulically-propelled endoscope to evaluate Fallopian tube blockage. The ovarian test is designed to allow gynecologists to extract cells without fear of spreading cancer, addressing limits of transvaginal ultrasound and CA-125 blood tests. The Fallopian tube endoscope aims to determine the nature of blockages, avoid radiation exposure from X-rays, and enable in-office assessment by gynecologists, potentially lowering costs of fertility care. The company moved into the Fogarty Institute for Innovation to aid regulatory and reimbursement networking and to limit overhead. nVision projected FDA 510(k) clearance for the two Class II devices sometime in 2015. The company was founded and led by CEO Surbhi Sarna, who has patient experience informing product design and has been named to Forbes 30 Under 30 for science.

Total raised

$17M

Funding rounds

2

Latest round

Series B

Latest activity

Jul 2016